What ||| S:0 E:4 ||| WP
's  ||| S:4 E:7 ||| VBZ
new  ||| S:7 E:11 ||| JJ
in  ||| S:11 E:14 ||| IN
dermatological  ||| S:14 E:29 ||| JJ
therapy ||| S:29 E:36 ||| NN
?  ||| S:36 E:38 ||| .
Several  ||| S:38 E:46 ||| JJ
good-quality  ||| S:46 E:59 ||| JJ
randomised  ||| S:59 E:70 ||| JJ
trials  ||| S:70 E:77 ||| NNS
brought  ||| S:77 E:85 ||| VBD
useful  ||| S:85 E:92 ||| JJ
information  ||| S:92 E:104 ||| NN
on  ||| S:104 E:107 ||| IN
how  ||| S:107 E:111 ||| WRB
to  ||| S:111 E:114 ||| TO
manage  ||| S:114 E:121 ||| VB
severe  ||| S:121 E:128 ||| JJ
skin  ||| S:128 E:133 ||| NN
infections  ||| S:133 E:144 ||| NNS
and  ||| S:144 E:148 ||| CC
develop  ||| S:148 E:156 ||| VB
anti-staphylococcus  ||| S:156 E:176 ||| JJ
strategies ||| S:176 E:186 ||| NNS
.  ||| S:186 E:188 ||| .
Trials  ||| S:188 E:195 ||| NNS
on  ||| S:195 E:198 ||| IN
common  ||| S:198 E:205 ||| JJ
warts  ||| S:205 E:211 ||| NNS
did  ||| S:211 E:215 ||| VBD
not  ||| S:215 E:219 ||| RB
bring  ||| S:219 E:225 ||| VB
any  ||| S:225 E:229 ||| DT
valuable  ||| S:229 E:238 ||| JJ
solution ||| S:238 E:246 ||| NN
.  ||| S:246 E:248 ||| .
Rituximab  ||| S:248 E:258 ||| NNP
and  ||| S:258 E:262 ||| CC
omalizumab  ||| S:262 E:273 ||| NNS
have  ||| S:273 E:278 ||| VBP
seen  ||| S:278 E:283 ||| VBN
their  ||| S:283 E:289 ||| PRP$
indications  ||| S:289 E:301 ||| NNS
becoming  ||| S:301 E:310 ||| VBG
more  ||| S:310 E:315 ||| RBR
precise  ||| S:315 E:323 ||| JJ
or  ||| S:323 E:326 ||| CC
broadened ||| S:326 E:335 ||| VBD
.  ||| S:335 E:337 ||| .
Meta-analyses  ||| S:337 E:351 ||| NNS
have  ||| S:351 E:356 ||| VBP
been  ||| S:356 E:361 ||| VBN
particularly  ||| S:361 E:374 ||| RB
numerous ||| S:374 E:382 ||| JJ
,  ||| S:382 E:384 ||| ,
but  ||| S:384 E:388 ||| CC
most  ||| S:388 E:393 ||| JJS
of  ||| S:393 E:396 ||| IN
the  ||| S:396 E:400 ||| DT
time  ||| S:400 E:405 ||| NN
with  ||| S:405 E:410 ||| IN
no  ||| S:410 E:413 ||| DT
decisive  ||| S:413 E:422 ||| JJ
conclusion ||| S:422 E:432 ||| NN
,  ||| S:432 E:434 ||| ,
since  ||| S:434 E:440 ||| IN
this  ||| S:440 E:445 ||| DT
methodology  ||| S:445 E:457 ||| NN
presents  ||| S:457 E:466 ||| VBZ
strong  ||| S:466 E:473 ||| JJ
limitations  ||| S:473 E:485 ||| NNS
for  ||| S:485 E:489 ||| IN
studying  ||| S:489 E:498 ||| VBG
safety  ||| S:498 E:505 ||| NN
data ||| S:505 E:509 ||| NNS
.  ||| S:509 E:511 ||| .
Most  ||| S:511 E:516 ||| RBS
important  ||| S:516 E:526 ||| JJ
work  ||| S:526 E:531 ||| NN
has  ||| S:531 E:535 ||| VBZ
been  ||| S:535 E:540 ||| VBN
rather  ||| S:540 E:547 ||| RB
directed  ||| S:547 E:556 ||| VBN
toward  ||| S:556 E:563 ||| IN
analysing  ||| S:563 E:573 ||| JJ
safety  ||| S:573 E:580 ||| NN
data  ||| S:580 E:585 ||| NNS
rather  ||| S:585 E:592 ||| RB
than  ||| S:592 E:597 ||| IN
efficacy ||| S:597 E:605 ||| NN
.  ||| S:605 E:607 ||| .
Among  ||| S:607 E:613 ||| IN
the  ||| S:613 E:617 ||| DT
most  ||| S:617 E:622 ||| RBS
important  ||| S:622 E:632 ||| JJ
results ||| S:632 E:639 ||| NNS
,  ||| S:639 E:641 ||| ,
are  ||| S:641 E:645 ||| VBP
those  ||| S:645 E:651 ||| DT
from  ||| S:651 E:656 ||| IN
a  ||| S:656 E:658 ||| DT
retrospective  ||| S:658 E:672 ||| JJ
cohort  ||| S:672 E:679 ||| NN
of  ||| S:679 E:682 ||| IN
patients  ||| S:682 E:691 ||| NNS
taking  ||| S:691 E:698 ||| VBG
isotretinoin ||| S:698 E:710 ||| NNS
:  ||| S:710 E:712 ||| :
suicidal  ||| S:712 E:721 ||| JJ
risk  ||| S:721 E:726 ||| NN
has  ||| S:726 E:730 ||| VBZ
to  ||| S:730 E:733 ||| TO
be  ||| S:733 E:736 ||| VB
linked  ||| S:736 E:743 ||| VBN
to  ||| S:743 E:746 ||| TO
severe  ||| S:746 E:753 ||| JJ
acne  ||| S:753 E:758 ||| NN
itself ||| S:758 E:764 ||| PRP
,  ||| S:764 E:766 ||| ,
rather  ||| S:766 E:773 ||| RB
than  ||| S:773 E:778 ||| IN
to  ||| S:778 E:781 ||| TO
the  ||| S:781 E:785 ||| DT
drug ||| S:785 E:789 ||| NN
.  ||| S:789 E:791 ||| .
